ATOS - ATOSSA THERAPEUTICS, INC.

QQQ $ 452.92 $ 4.00 (0.89 %)

DIA $ 398.64 $ 0.76 (0.19 %)

SPY $ 529.21 $ 3.29 (0.63 %)

TLT $ 92.16 $ 0.32 (0.35 %)

GLD $ 220.86 $ 1.63 (0.74 %)

Previous Close

$ 1.54

Open

$ 1.60

Bid

$ 1.64 x 1,500

Ask

$ 1.68 x 732

Day's Range

$ 1.60 - $ 1.68

52 Week Range

$ 0.62 - $ 2.31

Volume

1,441,648

Average Volume

Market Cap

192.99M

Beta (5Y Monthly)

$ 1.60

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-13-2024	03-31-2024	10-Q
2	04-01-2024	12-31-2023	10-K
3	11-13-2023	09-30-2023	10-Q
4	08-14-2023	06-30-2023	10-Q
5	05-15-2023	03-31-2023	10-Q
6	03-22-2023	12-31-2022	10-K
7	11-07-2022	09-30-2022	10-Q
8	08-08-2022	06-30-2022	10-Q
9	05-09-2022	03-31-2022	10-Q
10	02-28-2022	12-31-2021	10-K
11	11-15-2021	09-30-2021	10-Q
12	08-13-2021	06-30-2021	10-Q
13	05-14-2021	03-31-2021	10-Q
14	03-31-2021	12-31-2020	10-K
15	11-13-2020	09-30-2020	10-Q
16	08-13-2020	06-30-2020	10-Q
17	05-13-2020	03-31-2020	10-Q
18	03-26-2020	12-31-2019	10-K
19	11-13-2019	09-30-2019	10-Q
20	08-13-2019	06-30-2019	10-Q
21	05-13-2019	03-31-2019	10-Q
22	03-28-2019	12-31-2018	10-K
23	11-14-2018	09-30-2018	10-Q
24	08-13-2018	06-30-2018	10-Q
25	05-14-2018	03-31-2018	10-Q
26	03-08-2018	12-31-2017	10-K
27	11-13-2017	09-30-2017	10-Q
28	08-14-2017	06-30-2017	10-Q
29	05-11-2017	03-31-2017	10-Q
30	03-16-2017	12-31-2016	10-K
31	11-14-2016	09-30-2016	10-Q
32	08-12-2016	06-30-2016	10-Q
33	05-05-2016	03-31-2016	10-Q
34	03-30-2016	12-31-2015	10-K
35	11-12-2015	09-30-2015	10-Q
36	08-06-2015	06-30-2015	10-Q
37	05-13-2015	03-31-2015	10-Q
38	03-30-2015	12-31-2014	10-K
39	11-12-2014	09-30-2014	10-Q
40	08-12-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Atossa Therapeutics Last Patient Its Phase...
05/15/2024 12:39:30

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced that the last patient in th...

Cantor Fitzgerald Reiterates Overweight on...
05/14/2024 13:25:09

Cantor Fitzgerald analyst Louise Chen reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Overweight.

HC Wainwright & Co. Maintains Buy on Atoss...
05/13/2024 16:54:59

HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price tar...

Atossa Therapeutics Q1 2024 Adj EPS $(0.05...
05/13/2024 12:54:22

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $...

Atossa Therapeutics Announces Support Of N...
05/07/2024 12:46:50

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced its support of new guidelin...

Atossa Therapeutics Announces Expanded Res...
04/29/2024 12:34:28

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced an expanded research agreem...

HC Wainwright & Co. Reiterates Buy on Atos...
04/16/2024 15:01:19

HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $4 price ...

Atossa Therapeutics And Quantum Leap Healt...
04/15/2024 12:39:34

The new study arm will enroll approximately 20 women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Gr...

Atossa Therapeutics Presents Data From 40m...
04/09/2024 16:00:06

The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen...

HC Wainwright & Co. Maintains Buy on Atoss...
04/02/2024 12:36:55

HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $4 price t...

Atossa Therapeutics Provides Five-Year (Z)...
03/19/2024 12:32:31

Atossa Therapeutics Regains Compliance Wit...
03/18/2024 12:31:45

Data From Atossa's Phase 2 EVANGELINE Clin...
03/06/2024 13:31:01

Atossa Therapeutics Announces First Patien...
02/22/2024 13:35:05

HC Wainwright & Co. Initiates Coverage On ...
02/12/2024 12:39:46

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and a...

Atossa Therapeutics Fully Enrolls (Z)-Endo...
02/07/2024 13:32:14

Atossa Therapeutics Issues Letter To Share...
01/09/2024 13:46:39

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of...

Atossa Therapeutics Announces Full Enrollm...
11/20/2023 13:31:16

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of...

Atossa Therapeutics Q3 EPS $(0.05) Beats $...
11/13/2023 14:04:46

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $...

Atossa Therapeutics Announces Greg Weaver ...
10/06/2023 20:07:23

-SEC Filing